Trials / Conditions / Stage IV Renal Cell Cancer AJCC v7

Stage IV Renal Cell Cancer AJCC v7

20 registered clinical trials studyying Stage IV Renal Cell Cancer AJCC v7.

Status	Trial	Sponsor	Phase
Terminated	Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastat NCT03334409	Academic and Community Cancer Research United	Phase 2
Terminated	Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizuma NCT03050060	University of Washington	Phase 2
Completed	Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer NCT03015740	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients NCT02599779	Sunnybrook Health Sciences Centre	Phase 2
Active Not Recruiting	Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic NCT02721732	M.D. Anderson Cancer Center	Phase 2
Completed	Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed NCT02761057	National Cancer Institute (NCI)	Phase 2
Terminated	Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery NCT02595918	National Cancer Institute (NCI)	Phase 1
Completed	Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer NCT02626130	M.D. Anderson Cancer Center	EARLY_Phase 1
Active Not Recruiting	Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney NCT02210117	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or M NCT01835158	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease Aft NCT01575548	National Cancer Institute (NCI)	Phase 3
Completed	Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533	National Cancer Institute (NCI)	Phase 1
Completed	Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Tr NCT01664182	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Aerosolized Aldesleukin in Treating Patients With Lung Metastases NCT01590069	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostat NCT01480154	National Cancer Institute (NCI)	Phase 1
Terminated	Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer NCT01239342	National Cancer Institute (NCI)	Phase 2
Terminated	Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After NCT01198158	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer NCT01038778	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer NCT00378703	National Cancer Institute (NCI)	Phase 2
Completed	Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cance NCT00121251	National Cancer Institute (NCI)	Phase 1 / Phase 2